Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ONCT-534 by Oncternal Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
ONCT-534 is under clinical development by Oncternal Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...